

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

PREPARATION FOR THE 2019  
INTERNATIONAL COOPERATION ON COSMETICS  
REGULATION (ICCR)

DATE: Wednesday, June 5, 2019  
TIME: 2:03 p.m.  
LOCATION: United States Food and Drug  
Administration  
5001 Campus Drive, Wiley  
Auditorium  
1st Floor  
College Park, MD 20740  
REPORTED BY: Natalia Thomas, Notary Public  
JOB No.: 3282481

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

## A P P E A R A N C E S

ON BEHALF OF FDA, Center for Cosmetics and Colors

JONATHAN HICKS, Office of Cosmetics

and Colors, FDA, HSF-125, 5001 Campus

Drive, College Park, MD 20740

Jonathan.hicks@fda.hhs.gov

## CONTENTS

PAGE

Linda Katz, MD, MPH, Director, Office of

Cosmetics &amp; Colors, FDA

3

Jay Ansell, PhD, DABT, Personal Care

17

Products Council

Deborah Campbell, CRNP, MSN, President,

21

American Cosmetic Manufacturers

Association

27

Mary Hilley, Humane Society of the U.S.,

## 1 P R O C E E D I N G S

2 DR. KATZ: Good afternoon. I'm Linda Katz.  
3 I'm the Director for the Office of Cosmetics and  
4 Colors here at the FDA. Everyone who's here,  
5 hopefully is here for the public meeting that we're  
6 having in preparation of the 2019 International  
7 Cooperation on Cosmetics Regulation, ICCR-13 meeting,  
8 which will happen in July in Montreal.

9 Before we get started, I just wanted to go  
10 ahead and clear up some housekeeping items. If  
11 everyone can turn off cell phones, other personal  
12 electronics they have so as not to disturb the people  
13 who will be speaking, I would appreciate it.

14 If for whatever reason you need to leave the  
15 room to either use the facilities or to leave in  
16 general, please go up towards the back of the room and  
17 someone will escort you towards the front door, or  
18 wherever else you may need to go.

19 So, with that I'd like to go ahead and get  
20 started. Okay, let me begin -- and what I'm going to  
21 do in the next, probably 10 minutes or so, is talk  
22 about ICCR or the International

1 Cooperation on Cosmetic Regulation.

2           What I will do, in the time that I have, is  
3 talk about ICCR and its process. I'll go through the  
4 summary of ICCR-12 and the outcomes. I will describe a  
5 little bit about the upcoming issues for the ICCR-13  
6 meeting that will be coming up as I said next month in  
7 Montreal, and give some instructions at the end for  
8 submitting items to ICCR for proposals for the future  
9 discussions.

10           So, let me begin. ICCR started as an  
11 offshoot of FDA's policy on international  
12 harmonization, which was -- began, back in October of  
13 1995. At that time, the FDA began to talk about how to  
14 have international harmonization amongst the varying  
15 products that it regulated, not just cosmetics, but  
16 also for foods, devices, drugs, et cetera.

17           And basically, the overarching goals were to  
18 include: facilitate international trade and promote  
19 mutual understanding, facilitation of the exchange of  
20 scientific and regulatory knowledge with  
21  
22

1 foreign government officials, and to promote  
2 transparency, to the extent permissible by law.  
3 Accept equivalent standards, such as compliance  
4 activities and enforcement programs of other countries  
5 if such programs met FDA's level of public health  
6 protection. And finally, which is key, to avoid  
7 lowering of public health protection afforded by U.S.  
8 law --that is, to avoid downward harmonization.

9 So, the first of the cosmetic international  
10 organizations that was established, was the Cosmetic  
11 Harmonization and International Cooperation, commonly  
12 known as CHIC, back in April of 1999.

13 The first meeting was held in Brussels, and  
14 the participants at that time were Canada, the European  
15 Union, Japan and the United States, specifically the  
16 FDA.

17 The goals were to introduce the different  
18 partners of international regulatory schemes, to seek  
19 areas of commonality for regulatory alignment and to  
20 develop a memorandum of cooperation.

21  
22 CHIC met three times, the last was in Canada

1 in 2005. Back in 2005, when we met for the last time as  
2 CHIC, the group decided that CHIC was nice, we got to  
3 know each other and we got to form regulatory  
4 relationships, but that we really never solved anything,  
5 and the meetings became more of a process to inform each  
6 other. We weren't really established in such a way as to  
7 get any agenda items accomplished or to work on any  
8 specific items.

9 So, in 2005 we decided we would disband CHIC  
10 and form ICCR. And we actually established ICCR in 2006  
11 and held its first meeting in 2007. The members at that  
12 time were the four members of CHIC which included  
13 Canada, the European Union, Japan and the United States.

14 In 2014, Brazil became the fifth member of the  
15 Steering Committee. We formed a term of reference, and  
16 we decided that we would set up our standards using a  
17 voluntary consensus model. And we would model ourselves  
18 off of other international harmonization groups at the  
19 time, which included ICH, VICH, GHDF.

20  
21  
22 And that basically, the one exception, that we

1 had from the other groups, was that we were going to  
2 get integral input from our industry trade partners --  
3 our industry trade associations. The goal was still  
4 to remove any regulatory obstacles among regions and  
5 to minimize the obstacles to international trade while  
6 retaining the highest level of consumer protection.

7 And again, we were to avoid downward  
8 harmonization. We also agreed as part of our voluntary  
9 consensus, that we would not deal with any issues that  
10 required changes in one area's regulatory schemes.

11 So, that the areas that we chose to work on  
12 would be areas that we could choose to have alignment  
13 or cooperation, rather than having to adopt someone's  
14 current regulations.

15 The ICCR work process is: the meetings  
16 rotate amongst the five regions, and in another slide,  
17 I'll show you where we've been over the last 13 years.  
18 We would hold an annual meeting and have interim  
19 telephone conferences, usually quarterly, hosted by  
20 the country or region chairing the ICCR meeting. They  
21 would provide for the  
22

1 Secretariat function for that year.

2 ICCR also may charter subsidiary working  
3 groups, and that the U.S. had agreed when we formed  
4 ICCR, that we would hold a public meeting such as this  
5 one, prior to the actual ICCR meeting to allow  
6 for stakeholders to participate and to give us  
7 information that they would like for us to share with  
8 the rest of the ICCR members.

9 The public meeting, as you saw, was published  
10 in the Federal Register. The structure of the annual  
11 meeting is as follows. The first day is a regulators-  
12 only meeting. The second day is regulators plus  
13 industry. The third day is a regulators' meeting only.  
14 At that time we would adopt the outcomes of the meeting  
15 at the close, prepare press releases or any other  
16 additional information that we would like to make sure  
17 got posted publicly.

18 In addition, we began a stakeholder open  
19 session that would be held on day two, for stakeholder  
20 participation. Usually this includes only stakeholders  
21 from the jurisdictions chairing the meeting.

22



1           The outcomes of the ICCR meeting now are  
2 posted on ICCR's website. I've left you the website  
3 information here, which shows the deliverables, the  
4 accepted documents and any other useful information  
5 that we've had over the course of a year.

6           Prior to the time of having the ICCR website,  
7 we would make all of the information that was pertinent  
8 available publicly, in the form of a press release.

9           So, these are locations of where we've been.  
10 As you can see, ICCR-1 started in Brussels and last  
11 year we were in Tokyo, and this year we will be in  
12 Montreal, Canada.

13           Just to highlight, the last one that U.S.  
14 hosted, was ICCR-10, and we will be hosting ICCR-15, as  
15 a coming attraction. These are all of the individuals  
16 who participated in ICCR-12 in Tokyo, and this includes  
17 not only the regulators, but also our industry  
18 partners.

19           The ICCR-12 agenda basically had the  
20  
21  
22

1 following items: Integrated strategies for safety  
2 assessment of cosmetic ingredients; Analytical test  
3 methods; Cosmetic product preservation; Allergens;  
4 Communications; the Microbiome; Updates from observing  
5 regulators; Industry update on e-commerce, and  
6 stakeholder presentations.

7 I'll go through in a little bit more detail  
8 just to summarize what occurred. So, with regard to the  
9 Integrated Strategies for Safety Cosmetic Ingredients,  
10 the ICCR's Steering Committee adopted the Integrated  
11 Strategies for Safety Assessment of Cosmetic  
12 Ingredients - Part II.

13 This is a white paper or report which  
14 describes strengths and limitations of new  
15 methodologies and it was posted to the ICCR website. In  
16 addition, ICCR Steering Committee agreed that the  
17 current work of the Joint Working Group would continue  
18 on, and it would form the case study -- that would be  
19 discussed at the next ICCR meeting as Part III.

20 As part of the preparation for the items in  
21 Part III, a meeting is being held in Canada on the 11th  
22

1 and part of the 12th to go over some of the information  
2 and to work on the case studies to help formulate the  
3 next white paper.

4 The Analytical Test Methods was also  
5 discussed. The Steering Committee accepted the Review  
6 of International Standards on Analytical Methods  
7 defined by ISO.

8 The report itself was endorsed and three ISO  
9 standards were endorsed and posted on our website after  
10 agreeing with the validation criteria.

11 ICCR also agreed to open the Joint Working  
12 Group to update a table of relevant ISO standards that  
13 could be used in the future.

14 The next report was Cosmetic Product  
15 Preservation. The Steering Committee agreed that the  
16 current Joint Working Group would continue to work on a  
17 white paper that will establish and evaluate the  
18 relative cosmetic preservation, preservative pallet.  
19 This arose from information that we had on cosmetic  
20 preservation, and the need to try to figure out which  
21 preservatives still could be used and would be

22

1 safe to be used in cosmetics and to what degree.

2 The Allergens work group -- the Steering  
3 Committee agreed that the Joint Working Group's  
4 assessment of non-animal methods in the evaluation  
5 of skin sensitization potential -- that report is going  
6 to be continued to be worked on and eventually will be  
7 posted on the website.

8 For Communications, the ICCR agreed to create  
9 a new Joint Working Group on communications that would  
10 include topics related to cosmetics for a broad  
11 audience. What this basically means is that we're  
12 trying to think of a way that all of us can  
13 communicate some of the same messaging to all of our  
14 constituents, so that if there is a message that we  
15 want to get out, everyone will see the same thing  
16 worldwide.

17 The Microbiome is a new Joint Work Group,  
18 and this was established during the cycle. It will be  
19 presenting the outcomes at the meeting coming in July.

20 From the observing countries or  
21 regulators, we heard from Israel, South Africa, South  
22 Korea, Taiwan, and Thailand. Israel discussed their  
license

1 and registration program. South Africa discussed  
2 harmonization with some of the European Commission  
3 regulations.

4 South Korea talked about their notable growth  
5 in export market. Taiwan discussed their new cosmetic  
6 act, animal testing ban and upcoming notification  
7 requirements. And Thailand talked about their  
8 harmonization and free trade issues with the  
9 Association of Southeast Asian Nations known as ASEAN.

10 Industry presented an update on e-commerce  
11 which is a way to facilitate cooperation and increase  
12 global consumer protection. These presentations were  
13 intended to stimulate discussion which they did, but  
14 there was also some concern that some of the areas in  
15 the discussion went beyond the jurisdiction of those at  
16 the table. The suggestion was to table it right now and  
17 perhaps at some point in time we would evaluate it  
18 again.

19 With regard to stakeholder presentations --  
20 the bulk of the presentations made by stakeholders  
21 were on animal testing, and what other alternatives  
22 could be done to avoid testing or minimizing animal

1 testing itself.

2           And it's important to note that ICCR has  
3 recognized the importance of alternatives to animal  
4 testing, and it continues to work on this topic. In  
5 the past, we've posted information as to what  
6 alternative tests can be done that have been validated.

7           Some of the specific tests are that are being  
8 looked at now are being done in a variety of different  
9 subgroups as opposed to one specific alternative  
10 subgroup which previously had met in the past.

11           With regard to last year, we had an  
12 International Symposium on Cosmetic Regulation that  
13 followed the ICCR-12 meeting. Japan decided to host  
14 such a meeting in which representatives from the ICCR  
15 jurisdictions participated. The event was open to  
16 Japanese cosmetic industry, academics and others who  
17 felt that they would like to come and hear what the  
18 regulators had to say.

19           So, that brings us up to ICCR-13. As I  
20 mentioned, Canada is hosting this year in Montreal and  
21  
22

1 it will be from July 9 to 11. During this past cycle,  
2 we've had quarterly interim teleconferences, and the  
3 work groups have continued to meet to create the  
4 documents and the information that will be presented at  
5 the upcoming meeting.

6 The agenda is as follows. We will continue  
7 to talk about the integrated strategies for safety  
8 assessment of cosmetic ingredients. We will continue  
9 to talk about cosmetic product preservation, allergens,  
10 international standards, communication, microbiome and  
11 any other new proposed agenda items that are proposed  
12 before the meeting time.

13 Finally, what I'd like to do before I get to  
14 the website one more time, is to show a slide with  
15 instructions for submitting future ICCR action items.  
16 Years ago, as there are some people in the audience  
17 who may remember, on our previous website we did have  
18 instructions for how to submit an action item, or  
19 agenda item for those who had something for us to  
20 consider.

21 For whatever reason, when the ICCR website  
22 was migrated, it seemed to have disappeared. But the

1 bottom line is that the FDA does invite public input  
2 on future ICCR agenda items. If there are specific  
3 items that you wish to have considered as part of an  
4 agenda item, please let us know. That should be done in  
5 writing to Jonathan Hicks and I have his email here.

6 If after this meeting, you think about it and  
7 have a formal item that you would also like to have  
8 discussed either at the next ICCR meeting, ICCR-13, or  
9 ICCR-14, please make those written requests as well to  
10 Jonathan Hicks and we will make sure that the Chair or  
11 the Secretary of the next ICCR meeting is informed.

12  
13  
14 The one thing that I will suggest is that if  
15 you're going to make a request, the request needs to  
16 be specific enough so we know what the questions are  
17 that someone would like to have ICCR address, and if  
18 there's any supporting information that you have that  
19 the ICCR needs to review to be able to talk about  
20 the topic, please submit that as well.

21  
22 And one last thing is again remember that we



1 cannot recommend changes to member laws or  
2 regulations. This slide shows our ICCR website and  
3 actually it's organized so that you could find out  
4 about all of us. It talks about the composition of  
5 ICCR, the Chairmanship and who's led which meeting.

6 All of the topics and any documents that  
7 we've agreed to have been posted on that website. I  
8 thank you for your attention and let me now turn over  
9 to our next speaker who would be Jay Ansell, from  
10 Personal Care Products Council.

11 DR. ANSELL: Thank you Linda. So, good  
12 afternoon. My name is Jay Ansell, and I'm the Vice  
13 President for Cosmetic Programs at the Personal Care  
14 Products Council. I'd like to thank FDA for holding  
15 this meeting and for its interest in soliciting the  
16 viewpoint on ICCR processes from the stakeholders.

17 On behalf of our industry, I am pleased to  
18 once again take this opportunity to emphasize our  
19 industry's strong support for the ICCR process. We  
20 would also like to express appreciation to FDA and to  
21 the other participating regulators from Europe, Japan,  
22 Brazil and Canada for their participation and support

1 of the ICCR process.

2 We believe ICCR has been and will continue to  
3 be a beneficial forum for the exchange of information  
4 and regulatory alignment between important markets for  
5 cosmetic and personal care products.

6 As a brief introduction, the Personal Care  
7 Products Council is the leading national trade  
8 association representing the global cosmetic and  
9 personal care products industry. Founded in 1894, our  
10 more than 600-member companies manufacture, distribute  
11 and supply the vast majority of finished personal care  
12 products marketed in the U.S.

13 For more than 100 years, regulators,  
14 policymakers, have relied on our organization to  
15 deliver honest, credible, accurate, scientific  
16 information about cosmetics and personal care  
17 products. We take this responsibility very seriously.

18 And we were pleased to represent our industry  
19 in the ICCR process. Now, the cosmetic and personal  
20 care industry is truly a global industry, and as such  
21 we are dependent on open markets and transparent,  
22 consistent regulatory environments around the world.

1           Our member companies continually strive to  
2 uphold and to surpass the most stringent regulatory  
3 standards worldwide, providing consumers with the  
4 safe, innovative and high-quality cosmetic and  
5 personal care products they've come to expect.

6           International harmonization is a critical  
7 component to the success of our industry. It promotes  
8 continual technologic innovation and benefits  
9 consumers around the world.

10           For all these reasons, PCPC is actively  
11 engaged in the international effort to align global  
12 safety and regulatory standards for consumers to  
13 eliminate trade barriers, and to ensure a level  
14 playing field for member companies while at the same  
15 time reinforcing consumer confidence in product  
16 safety.

17           The stated mission of ICCR is to maintain  
18 the highest level of global consumer protection while  
19 minimizing barriers to international trade  
20 underscores the important role of FDA and other  
21 regulators in this global environment.

22           We believe that the ICCR has served as an

1 important forum for aligning regulations, policies and  
2 guidelines affecting our industry. And importantly,  
3 as a resource for other countries looking to align  
4 their regulatory approaches around such common  
5 guidelines.

6 We are looking forward to the results of  
7 the ICCR-13 meeting. As mentioned -- we look towards  
8 an endorsement of a report regarding cosmetic  
9 preservation, continued advancement of alternative  
10 safety assessment tools for identifying potential  
11 dermal allergens, and continuing the dialogue in the  
12 exciting new work item on the microbiome.

13 Let me add ICCR-13 will also have an  
14 important workshop on integrated strategies for  
15 safety assessment of cosmetic ingredients. The  
16 important work undertaken by ICCR has been recognized  
17 by industry and regulators in other countries who  
18 have reviewed the documents and now, themselves,  
19 express interest in participating in the ICCR  
20 meetings.

21 And we're particularly pleased to welcome  
22 to the ICCR-13, representatives from Argentina,  
Chili, Columbia, Israel, South Korea, South Africa,  
Taiwan

1 and Thailand as observers to the meeting.

2 Our industry fully supports the participation  
3 of these other countries in the ICCR process and we  
4 are interested to explore other avenues to promote the  
5 ICCR work globally, as well as considering synergies  
6 between ICCR and other international organizations,  
7 for example, ISO.

8 As international trade and cosmetic and  
9 personal care products continues to expand, achieving  
10 the goal of global harmony, as regulatory alignment  
11 becomes more critical.

12 And we look forward to working with FDA and  
13 the other regulators to enhance the ICCR process in  
14 the months and years ahead, thank you.

15 DR. KATZ: Thank you Jay. Next, we will hear  
16 from Deborah Campbell.

17 MS. CAMPBELL: Hello everyone. I'm Deborah  
18 Campbell, President of the American Cosmetic  
19 Manufacturers Association located in Washington, D.C.  
20 ACMA is a non-profit organization that supports U.S.  
21 cosmetic manufacturers and assists them to expand  
22 their businesses in the global market.

1           Since ACMA was founded in 2010, our members  
2           have relied upon our organization to deliver the  
3           latest standards and regulations set by the FDA for  
4           the manufacture and labeling of cosmetic products and  
5           encouraging them to uphold consumer protection by  
6           producing the highest quality products.

7           On the behalf of all ACMA members, I would  
8           like to thank the FDA and the Office of Cosmetics and  
9           Colors for their efforts in planning this meeting.  
10          ACMA appreciates the consideration that the FDA has  
11          shown by holding these annual meetings that give  
12          cosmetic industries and interested private parties, a  
13          venue to voice their cosmetic-related concerns before  
14          the ICCR Conferences are held.

15          ACMA would also like to express appreciation  
16          for the efforts of ICCR members in supporting the  
17          international cosmetic industry while ensuring  
18          customer safety.

19          The participation of new representatives from  
20          Thailand, South Korea, Israel, Taiwan and South  
21          Africa, and I believe Columbia, as observed in ICCR-  
22          12, highlights the interest of ICCR to reach out to

1 different regions in an attempt to achieve global  
2 harmonization of cosmetic regulations.

3 ACMA strongly supports the outcomes of ICCR-  
4 12, held in Tokyo, concerning the integrated  
5 strategies for safety assessments of cosmetic  
6 ingredients, analytical test methods and allergens.

7 ACMA is pleased to participate in this  
8 preparation meeting for ICCR-13, to speak on the  
9 behalf of our members and act as their voice to  
10 address their interests.

11 In preparation for this meeting, ACMA  
12 conducted a survey of our members to detect some  
13 issues that they have encountered while marketing  
14 their products.

15 The results of the survey shed light on some  
16 issues facing the majority of our members. Members  
17 exporting to Europe reported difficulties meeting EU  
18 directives regarding cosmetic testing, labeling and  
19 the different cosmetic export requirements of certain  
20 countries within the EU itself.

21 ACMA believes that a regulatory framework in  
22 the safety and distribution of cosmetic products are

1 the most important factors for the growth of the  
2 cosmetic industry. The safety of cosmetic products  
3 are regulated by diverse regulatory bodies around the  
4 globe which all have their own rules and regulations.

5 Both the European Union and the United States  
6 regulate the manufacture and distribution of cosmetic  
7 products in a way that provides consumers with the  
8 high-quality products in a high degree of safety.  
9 However, because both markets have slight variations,  
10 some U.S. companies find it time consuming and costly  
11 to comply with EU regulations, especially small and  
12 new cosmetic manufacturers.

13 The FDA regulates cosmetics under the  
14 authority of the Federal Food Drugs and Cosmetic Act  
15 and the Fair Packaging and Labeling Act. However, the  
16 FDA's approval is not required for the distribution of  
17 cosmetic products, ingredients and color additives in  
18 the market.

19 It is the manufacturer's responsibility to  
20 ensure the safety of its cosmetic products.  
21 Manufacturers follow guidelines and regulatory  
22 elements set by the FDA and international regulatory



1 bodies to ensure high-quality products, consumer  
2 safety, and the ability to market their products  
3 internationally.

4           However, many believe that the EU, European  
5 Union, is stricter in the regulation of cosmetic  
6 manufacturing citing EU Cosmetic Directive Annex 2  
7 that reveals a list of 1,300 banned ingredients in the  
8 manufacture of cosmetics and comparing it to the list  
9 of U.S.-banned ingredients that includes only 11  
10 materials.

11           But, after examination of both lists, you'll  
12 find that the European Union has listed a vast number  
13 of ingredients which have never been used in cosmetic  
14 manufacturing, such as aircraft fuel, various  
15 petroleum refinery biproducts, and carbon monoxide.

16           Another difference between the United States  
17 and the European Union is how both regions define  
18 cosmetics. For example, some of ACMA's members that  
19 export sunscreen products to Europe, experience  
20 various regulatory hurdles as the FDA classifies  
21 sunscreens as drugs, while the EU allows the marketing  
22 of certain cosmetic products that contain some

1 medicinal effects.

2           You can imagine the amount of paperwork  
3 needed for a U.S. cosmetic exporter to market a  
4 product, classify those drugs in the United States and  
5 then market it in the European Union as a cosmetic  
6 product.

7           This same issue is applicable for other  
8 products such as anticaries toothpaste and lip balms.  
9 For this reason, ACMA supports ICCR efforts to achieve  
10 harmonization in the global regulation of cosmetic  
11 manufacturing and labeling.

12           ACMA respectfully requests that the FDA speak  
13 on our behalf of their concerns at ICCR-13. In  
14 summary, ACMA recognizes and appreciates the efforts  
15 of all attendees, FDA and Office of Cosmetic and Color  
16 staff, and ICCR members in the development and  
17 promotion of the international cosmetic industry.

18           ACMA plans to attend ICCR-14, to be on the  
19 front line of international trade regulation. Thank  
20 you for listening.

21           DR. KATZ: Thank you, and now we'll hear from  
22 our final speaker, Mary Hilley.

1 MS. HILLEY: Good afternoon. My name is Mary  
2 Hilley. Thank you for the opportunity to submit these  
3 comments on behalf of the Humane Society of the United  
4 States, the Humane Society Legislative Fund and our  
5 members and supporters.

6 More than 30 countries, including the member  
7 states of the European Union, India, Israel, Norway  
8 and Switzerland, with more than 1.8 billion residents,  
9 have passed laws banning the use of animal testing for  
10 cosmetics, as well as the sale or import of animal-  
11 tested cosmetics.

12 New Zealand, Guatemala, Australia and 7  
13 states in Brazil have also prohibited cosmetics animal  
14 testing. Rio is the first state in Brazil to also  
15 prohibit the sale of animal-tested cosmetics.

16 Turkey, South Korea and Taiwan have passed  
17 laws limiting cosmetic animal testing. In 2018,  
18 California became the first state in the country to  
19 prohibit the sale of animal-tested cosmetics.

20 We urge the FDA to push for global  
21 harmonization of laws to prohibit animal testing for  
22 cosmetics. HSUS and HSLF and very encouraged that the

1 U.S., Brazilian, Canadian, European and Japanese  
2 regulators continue to work together to discuss  
3 harmonization of cosmetic regulations and bring about  
4 the uniformity necessary to simplify regulatory  
5 burdens on companies selling internationally.

6 We encourage ICCR to solicit participation of  
7 additional countries, either as observers or Steering  
8 Committee members to ensure greater harmonization. We  
9 were happy to see that the recent report released by  
10 the industry and regulator's joint working group,  
11 Integrated Strategies for Safety Assessments of  
12 Cosmetic Ingredients - Part II, following the recent  
13 publication of principles in Part I.

14 This thorough review of the numerous new  
15 approached methodologies available is very instructive  
16 and should be helpful to industry in applying non-  
17 animal testing strategies to cosmetic safety  
18 assessment.

19 We were encouraged to see that further work  
20 is planned by this working group to develop case  
21 studies. These will only further clarify how a  
22 company can assure the safety of their ingredients

1 without the need for new animal test data.

2 We ask FDA to advocate for the continued  
3 development and regulatory acceptance of NAMS to  
4 assess cosmetics and their component ingredients. We  
5 would like to call your attention to a new project  
6 Human Society International is leading, with support  
7 from the Humane Society of the United States and the  
8 Humane Society Legislative Funds.

9 The non-animal cosmetic safety assessment  
10 globally by 2023, is a collaboration with leading  
11 stakeholders in the cosmetic's industry, including  
12 Avon Products, Estée Lauder, Firmenich, H&M, Loss  
13 Unlimited, Lush, Proctor and Gamble and Unilever.

14 This collaboration's aim is to achieve  
15 globally harmonized legislative measures to end  
16 cosmetic animal testing and trade, share information  
17 on decision-making approaches without new animal  
18 testing to develop real world case studies, and invest  
19 in education and training programs that will support  
20 complete safety assessment of cosmetics without new  
21 animal testing globally.

22 As part of this project, we are hoping to

1 work with FDA on identifying safety information needs,  
2 and in developing training materials. We would also  
3 welcome any other opportunities to work with FDA to  
4 bring about the acceptance and implementation of NAMS  
5 and educate regulators and the regulated-community  
6 alike on how to make risk-based cosmetic safety  
7 decisions without the need for new animal tests.

8 On behalf of the Humane Society family of  
9 organizations, thank you so much for your time.

10 DR. KATZ: Thank you, and that brings us to  
11 the end of our meeting as no others have requested  
12 previously to speak. Before I end, I'd like to take  
13 this opportunity to thank several people, only one of  
14 whom I see in the room, but I'd like to thank Jonathan  
15 Hicks for all his work on this as well as John Gasper  
16 from my staff and Juanita Yates who you met out at the  
17 registration desk.

18 So, thank you very much and thank you for  
19 attending.


20 (Whereupon, at 2:39 the meeting was concluded.)

21  
22

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

## CERTIFICATE OF NOTARY PUBLIC

I, NATALIA THOMAS, the officer before whom the foregoing proceedings were taken, do hereby certify that any witness(es) in the foregoing proceedings, prior to testifying, were duly sworn; that the proceedings were recorded by me and thereafter reduced to typewriting by a qualified transcriptionist; that said digital audio recording of said proceedings are a true and accurate record to the best of my knowledge, skills, and ability; that I am neither counsel for, related to, nor employed by any of the parties to the action in which this was taken; and, further, that I am not a relative or employee of any counsel or attorney employed by the parties hereto, nor financially or otherwise interested in the outcome of this action.



NATALIA THOMAS

Notary Public in and for the

STATE OF MARYLAND

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

## CERTIFICATE OF TRANSCRIBER

I, HELEN VENTURINI, do hereby certify that this transcript was prepared from the digital audio recording of the foregoing proceeding, that said transcript is a true and accurate record of the proceedings to the best of my knowledge, skills, and ability; that I am neither counsel for, related to, nor employed by any of the parties to the action in which this was taken; and, further, that I am not a relative or employee of any counsel or attorney employed by the parties hereto, nor financially or otherwise interested in the outcome of this action.



HELEN VENTURINI



<b>&amp;</b>	<b>3</b>	<b>actively</b> 19:10	<b>allow</b> 8:5
<b>&amp;</b> 2:12	<b>3</b> 2:12	<b>activities</b> 5:4	<b>allows</b> 25:21
<b>1</b>	<b>30</b> 27:6	<b>actual</b> 8:5	<b>alright</b> 3:20 4:2
<b>1</b> 9:13	<b>3282481</b> 1:13	<b>add</b> 20:13	<b>alternative</b> 14:6
<b>1,300</b> 25:7	<b>4</b>	<b>addition</b> 8:18	14:11 20:10
<b>1.8</b> 27:8	<b>402-1375</b> 2:8	10:16	<b>alternatives</b> 13:21
<b>10</b> 3:21 9:17	<b>4300</b> 2:5	<b>additional</b> 8:15	14:3
<b>100</b> 18:13	<b>5</b>	28:7	<b>american</b> 2:14
<b>11</b> 15:1 25:9	<b>5</b> 1:4	<b>additives</b> 24:17	21:18
<b>11th</b> 10:22	<b>5100</b> 1:8	<b>address</b> 16:17	<b>amount</b> 26:2
<b>12</b> 4:4 9:19,22	<b>6</b>	23:10	<b>analytical</b> 10:2
14:15 22:22 23:4	<b>600</b> 18:10	<b>administration</b>	11:4,6 23:6
<b>12th</b> 11:1	<b>7</b>	1:7	<b>animal</b> 12:4 13:6
<b>13</b> 3:7 4:6 7:18	<b>7</b> 27:12	<b>admission</b> 19:17	13:21,22 14:3
14:21 16:9 20:7	<b>9</b>	<b>adopt</b> 7:14 8:14	27:9,10,13,15,17
20:13,21 23:8	<b>9</b> 15:1	<b>adopted</b> 10:11	27:19,21 28:17
26:13	<b>a</b>	11:8	29:1,9,16,17,21
<b>14</b> 16:10 26:18	<b>ability</b> 25:2 31:10	<b>advancement</b> 20:9	30:7
<b>14519</b> 31:17	32:7	<b>advocate</b> 29:2	<b>annex</b> 25:6
<b>15</b> 9:17	<b>able</b> 16:19	<b>afforded</b> 5:8	<b>annual</b> 7:19 22:11
<b>17</b> 2:13	<b>academics</b> 14:18	<b>africa</b> 12:21 20:22	<b>ansell</b> 2:13 17:9
<b>17264</b> 32:14	<b>accept</b> 5:3	22:21	17:11,12
<b>1894</b> 18:9	<b>acceptance</b> 29:3	<b>african</b> 13:1	<b>anticaries</b> 26:8
<b>1995</b> 4:14	30:4	<b>afternoon</b> 3:2	<b>applicable</b> 26:7
<b>1999</b> 5:13	<b>accepted</b> 9:5 11:5	17:12 27:1	<b>applying</b> 28:16
<b>1st</b> 1:10	<b>accomplished</b> 6:8	<b>agenda</b> 6:7 9:22	<b>appreciate</b> 3:13
<b>2</b>	<b>accurate</b> 18:15	15:6,11,19 16:2,4	<b>appreciates</b> 22:10
<b>2</b> 25:6	31:9 32:5	<b>ago</b> 15:16	26:14
<b>2005</b> 6:1,1,9	<b>achieve</b> 23:1 26:9	<b>agreed</b> 7:8 8:3	<b>appreciation</b>
<b>2006</b> 6:11	29:14	10:16 11:10,12,16	17:20 22:15
<b>2007</b> 6:12	<b>achieving</b> 21:9	12:3,8 17:7	<b>approached</b> 28:15
<b>2010</b> 22:1	<b>acma</b> 21:20 22:1,7	<b>ahead</b> 3:10,19	<b>approaches</b> 20:4
<b>2014</b> 6:15	22:10,15 23:3,7	21:14	29:17
<b>2018</b> 27:17	23:11,21 26:9,12	<b>aim</b> 29:14	<b>approval</b> 24:16
<b>2019</b> 1:1,4 3:6	26:14,18	<b>aircraft</b> 25:14	<b>april</b> 5:13
<b>2023</b> 29:10	<b>acma's</b> 25:18	<b>align</b> 19:11 20:3	<b>areas</b> 5:20 7:12,13
<b>20740</b> 1:11 2:6	<b>act</b> 13:5 23:9	<b>aligning</b> 20:1	13:14
<b>21</b> 2:15	24:14,15	<b>alignment</b> 5:20	<b>area's</b> 7:10
<b>240</b> 2:8	<b>action</b> 15:15,18	7:13 18:4 21:10	<b>argentina</b> 20:21
<b>27</b> 2:17	31:12,16 32:8,12	<b>alike</b> 30:6	<b>asean</b> 13:9
<b>2:03</b> 1:5		<b>allergens</b> 10:3	<b>asian</b> 13:9
<b>2:39</b> 30:20		12:2 15:10 20:11	<b>assess</b> 29:4
		23:6	<b>assessment</b> 10:2
			10:12 12:4 15:8

20:10,15 28:18 29:9,20 <b>assessments</b> 23:5 28:11 <b>assists</b> 21:21 <b>association</b> 2:15 13:9 18:8 21:19 <b>associations</b> 7:3 <b>assure</b> 28:22 <b>attempt</b> 23:1 <b>attend</b> 26:18 <b>attendees</b> 26:15 <b>attending</b> 30:19 <b>attention</b> 17:8 29:5 <b>attorney</b> 31:14 32:10 <b>attraction</b> 9:18 <b>audience</b> 12:11 15:16 <b>audio</b> 31:8 32:3 <b>auditorium</b> 1:9 <b>australia</b> 27:12 <b>authority</b> 24:14 <b>available</b> 9:10 28:15 <b>avenues</b> 21:4 <b>avoid</b> 5:7,9 7:7 13:22 <b>avon</b> 29:12	<b>behalf</b> 2:2 17:17 22:7 23:9 26:13 27:3 30:8 <b>believe</b> 18:2 19:22 22:21 25:4 <b>believes</b> 23:21 <b>beneficial</b> 18:3 <b>benefits</b> 19:8 <b>best</b> 31:10 32:6 <b>beyond</b> 13:15 <b>billion</b> 27:8 <b>biproducs</b> 25:15 <b>bit</b> 4:5 10:8 <b>bodies</b> 24:3 25:1 <b>bottom</b> 16:1 <b>branch</b> 1:8 <b>brazil</b> 6:15 17:22 27:13,14 <b>brazilian</b> 28:1 <b>brief</b> 18:6 <b>bring</b> 28:3 30:4 <b>brings</b> 14:21 30:10 <b>broad</b> 12:10 <b>brussels</b> 5:14 9:13 <b>bulk</b> 13:20 <b>burdens</b> 28:5 <b>businesses</b> 21:22	<b>cell</b> 3:11 <b>center</b> 2:2,4 <b>certain</b> 23:19 25:22 <b>certificate</b> 31:1 32:1 <b>certify</b> 31:4 32:2 <b>cetera</b> 4:18 <b>chair</b> 7:22 16:11 <b>chairmanship</b> 17:5 <b>changes</b> 7:10 17:1 <b>charter</b> 8:2 <b>chic</b> 5:13,22 6:2,2 6:10,13 <b>chili</b> 20:21 <b>choose</b> 7:13 <b>chose</b> 7:12 <b>citing</b> 25:6 <b>clarify</b> 28:21 <b>classifies</b> 25:20 <b>classify</b> 26:4 <b>clear</b> 3:10 <b>close</b> 8:14 <b>collaboration</b> 29:10 <b>collaboration's</b> 29:14 <b>college</b> 1:11 2:6 <b>color</b> 24:17 26:15 <b>colors</b> 2:2,4,12 3:4 22:9 <b>columbia</b> 20:22 22:21 <b>come</b> 14:19 15:12 19:5 <b>coming</b> 4:6 9:18 12:19 <b>comments</b> 27:3 <b>commerce</b> 10:5 13:10 <b>commission</b> 13:2 <b>committee</b> 6:16 10:10,16 11:5,16	12:3 28:8 <b>common</b> 20:4 <b>commonality</b> 5:20 <b>commonly</b> 5:12 <b>communicate</b> 12:13 <b>communication</b> 15:10 <b>communications</b> 10:4 12:8,9 <b>community</b> 30:5 <b>companies</b> 18:10 19:1,14 24:10 28:5 <b>company</b> 28:22 <b>comparing</b> 25:8 <b>complete</b> 29:20 <b>compliance</b> 5:4 <b>comply</b> 24:11 <b>component</b> 19:7 29:4 <b>composition</b> 17:4 <b>concern</b> 13:14 <b>concerning</b> 23:4 <b>concerns</b> 22:13 26:13 <b>concluded</b> 30:20 <b>conducted</b> 23:12 <b>conferences</b> 7:20 7:20 22:14 <b>confidence</b> 19:15 <b>consensus</b> 6:18 7:9 <b>consider</b> 15:20 <b>consideration</b> 22:10 <b>considered</b> 16:3 <b>considering</b> 21:5 <b>consistent</b> 18:22 <b>constituents</b> 12:14 <b>consumer</b> 7:6 13:12 19:15,18 22:5 25:1
<b>b</b>	<b>c</b>		
<b>back</b> 3:16 4:13 5:13 6:1 <b>balms</b> 26:8 <b>ban</b> 13:6 <b>banned</b> 25:7,9 <b>banning</b> 27:9 <b>barriers</b> 19:13,19 <b>based</b> 30:6 <b>basically</b> 4:11,19 6:22 9:22 11:20 12:11 <b>began</b> 4:13,14 8:18	<b>c</b> 2:1 3:1 <b>california</b> 27:18 <b>call</b> 29:5 <b>campbell</b> 2:14 21:16,17,18 <b>canada</b> 5:16,22 6:13 9:15 10:22 14:22 17:22 <b>canadian</b> 28:1 <b>carbon</b> 25:15 <b>care</b> 2:13 17:10,13 18:5,6,9,11,16,20 19:5 21:9 <b>case</b> 10:18 11:2 28:20 29:18		

<p><b>consumers</b> 19:3,9 19:12 24:7</p> <p><b>consuming</b> 24:10</p> <p><b>contain</b> 25:22</p> <p><b>contents</b> 2:9</p> <p><b>continual</b> 19:8</p> <p><b>continually</b> 19:1</p> <p><b>continue</b> 10:17,18 11:17 15:7,9 18:2 28:2</p> <p><b>continued</b> 12:6 15:3 20:9 29:2</p> <p><b>continues</b> 14:4 21:9</p> <p><b>continuing</b> 20:11</p> <p><b>cooperation</b> 1:2 3:7 4:1 5:12,21 7:14 13:11</p> <p><b>cosmetic</b> 2:15 4:1 5:10,11 10:2,3,10 10:12 11:15,19,21 13:5 14:14,18 15:8,9 17:13 18:5 18:8,19 19:4 20:9 20:15 21:8,18,21 22:4,12,13,17 23:2,5,18,19,22 24:2,2,6,12,14,17 24:20 25:5,6,13 25:22 26:3,5,10 26:15,17 27:17 28:3,12,17 29:9 29:16 30:6</p> <p><b>cosmetics</b> 1:2 2:2 2:4,12 3:3,7 4:17 12:1,10 18:16 22:8 24:13 25:8 25:18 27:10,11,13 27:15,19,22 29:4 29:20</p> <p><b>cosmetic's</b> 29:11</p> <p><b>costly</b> 24:10</p> <p><b>couldn't</b> 6:5</p>	<p><b>council</b> 2:13 17:10 17:14 18:7</p> <p><b>counsel</b> 31:11,14 32:7,10</p> <p><b>countries</b> 5:5 12:20 20:3,17 21:3 23:20 27:6 28:7</p> <p><b>country</b> 7:21 27:18</p> <p><b>course</b> 9:6</p> <p><b>create</b> 12:8 15:3</p> <p><b>credible</b> 18:15</p> <p><b>criteria</b> 11:11</p> <p><b>critical</b> 19:6 21:11</p> <p><b>current</b> 10:17 11:17</p> <p><b>customer</b> 22:18</p> <p><b>cycle</b> 12:18 15:2</p> <p style="text-align: center;"><b>d</b></p> <p><b>d</b> 3:1</p> <p><b>d.c.</b> 21:19</p> <p><b>data</b> 29:1</p> <p><b>date</b> 1:4</p> <p><b>day</b> 8:11,12,13,19</p> <p><b>deal</b> 7:9</p> <p><b>deborah</b> 2:14 21:16,17</p> <p><b>decided</b> 6:2,9,17 14:15</p> <p><b>decision</b> 29:17</p> <p><b>decisions</b> 30:7</p> <p><b>define</b> 25:17</p> <p><b>defined</b> 11:7</p> <p><b>degree</b> 12:1 24:8</p> <p><b>deliver</b> 18:15 22:2</p> <p><b>deliverables</b> 9:5</p> <p><b>dependent</b> 18:21</p> <p><b>dermal</b> 20:11</p> <p><b>describe</b> 4:5</p> <p><b>describes</b> 10:14</p> <p><b>desk</b> 30:17</p> <p><b>detail</b> 10:8</p>	<p><b>detect</b> 23:12</p> <p><b>develop</b> 5:21 28:20 29:18</p> <p><b>developing</b> 30:2</p> <p><b>development</b> 26:16 29:3</p> <p><b>devices</b> 4:17</p> <p><b>dialogue</b> 20:11</p> <p><b>difference</b> 25:16</p> <p><b>different</b> 5:18 14:10 23:1,19</p> <p><b>difficulties</b> 23:17</p> <p><b>digital</b> 31:8 32:3</p> <p><b>directive</b> 25:6</p> <p><b>directives</b> 23:18</p> <p><b>director</b> 2:11 3:3</p> <p><b>disappeared</b> 15:22</p> <p><b>disband</b> 6:9,10</p> <p><b>discuss</b> 28:2</p> <p><b>discussed</b> 11:5 12:22 13:1,5 16:9</p> <p><b>discussion</b> 13:13 13:15</p> <p><b>discussions</b> 4:10</p> <p><b>distribute</b> 18:10</p> <p><b>distribution</b> 23:22 24:6,16</p> <p><b>disturb</b> 3:12</p> <p><b>diverse</b> 24:3</p> <p><b>documents</b> 9:5 15:4 17:6 20:18</p> <p><b>door</b> 3:17</p> <p><b>downward</b> 5:9 7:7</p> <p><b>drug</b> 1:6</p> <p><b>drugs</b> 4:17 24:14 25:21 26:4</p> <p><b>duly</b> 31:5</p> <p style="text-align: center;"><b>e</b></p> <p><b>e</b> 2:1,1 3:1,1 10:5 13:10</p> <p><b>educate</b> 30:5</p> <p><b>education</b> 29:19</p>	<p><b>effects</b> 26:1</p> <p><b>effort</b> 19:11</p> <p><b>efforts</b> 22:9,16 26:9,14</p> <p><b>either</b> 3:15 16:9 28:7</p> <p><b>electronics</b> 3:12</p> <p><b>elements</b> 24:22</p> <p><b>eliminate</b> 19:13</p> <p><b>email</b> 16:6</p> <p><b>emphasize</b> 17:18</p> <p><b>employed</b> 31:11 31:14 32:8,11</p> <p><b>employee</b> 31:13 32:10</p> <p><b>encountered</b> 23:13</p> <p><b>encourage</b> 28:6</p> <p><b>encouraged</b> 27:22 28:19</p> <p><b>encouraging</b> 22:5</p> <p><b>endorsed</b> 11:9,9</p> <p><b>endorsement</b> 20:8</p> <p><b>enforcement</b> 5:4</p> <p><b>engaged</b> 19:11</p> <p><b>enhance</b> 21:13</p> <p><b>ensure</b> 19:13 24:20 25:1 28:8</p> <p><b>ensuring</b> 22:17</p> <p><b>environment</b> 19:21</p> <p><b>environnents</b> 18:22</p> <p><b>equivalent</b> 5:3</p> <p><b>es</b> 31:4</p> <p><b>escort</b> 3:17</p> <p><b>especially</b> 20:8 24:11</p> <p><b>esquire</b> 2:3</p> <p><b>establish</b> 11:18</p> <p><b>established</b> 5:11 6:7,11 12:18</p> <p><b>estée</b> 29:12</p>
--	--	--	--

<b>et</b> 4:17	21:12 22:3,8,10	<b>framework</b> 23:21	<b>guatemala</b> 27:12
<b>eu</b> 23:17,20 24:11	24:13,22 25:20	<b>free</b> 13:8	<b>guidelines</b> 20:2,5
25:4,6,21	26:12,15 27:20	<b>front</b> 3:17 26:19	24:21
<b>europe</b> 17:21	29:2 30:1,3	<b>fuel</b> 25:14	<b>h</b>
23:17 25:19	<b>fda.hhs.gov</b> 2:7	<b>fully</b> 21:2	<b>h&amp;m</b> 29:12
<b>european</b> 5:16	<b>fda's</b> 4:12 5:5	<b>function</b> 8:1	<b>happen</b> 3:8
6:14 13:2 24:5	24:16	<b>fund</b> 2:17 27:4	<b>happy</b> 28:9
25:4,12,17 26:5	<b>federal</b> 8:10 24:14	<b>funds</b> 29:8	<b>harmonization</b>
27:7 28:1	<b>felt</b> 14:19	<b>further</b> 28:19,21	4:13,15 5:9,12
<b>evaluate</b> 11:18	<b>field</b> 19:14	31:13 32:9	6:20 7:8 13:2,8
13:18	<b>fifth</b> 6:15	<b>future</b> 4:9 11:14	19:6 23:2 26:10
<b>evaluation</b> 12:4	<b>figure</b> 11:21	15:15 16:2	27:21 28:3,8
<b>event</b> 14:17	<b>final</b> 26:22	<b>g</b>	<b>harmonized</b> 29:15
<b>eventually</b> 12:6	<b>finally</b> 5:7 15:13	<b>g</b> 3:1	<b>harmony</b> 21:10
<b>examination</b>	<b>financially</b> 31:15	<b>gamble</b> 29:13	<b>health</b> 5:6,8
25:11	32:11	<b>gasper</b> 30:15	<b>hear</b> 14:19 21:15
<b>example</b> 21:7	<b>find</b> 16:12 17:3	<b>general</b> 3:16	26:21
25:18	24:10 25:12	<b>ghdf</b> 6:21	<b>heard</b> 12:21
<b>exception</b> 6:22	<b>finished</b> 18:11	<b>give</b> 4:8 8:6 22:11	<b>held</b> 5:14 6:11
<b>exchange</b> 4:22	<b>firmenich</b> 29:12	<b>global</b> 13:12 18:8	8:19 10:22 22:14
18:3	<b>first</b> 5:10,14 6:11	18:20 19:11,18,21	23:4
<b>exciting</b> 20:12	8:11 27:14,18	21:10,22 23:1	<b>helen</b> 32:2,15
<b>expand</b> 21:9,21	<b>five</b> 7:17	26:10 27:20	<b>hello</b> 21:17
<b>expect</b> 19:5	<b>floor</b> 1:10	<b>globally</b> 21:5	<b>help</b> 11:2
<b>experience</b> 25:19	<b>follow</b> 24:21	29:10,15,21	<b>helpful</b> 16:21
<b>explore</b> 21:4	<b>following</b> 10:1	<b>globe</b> 24:4	28:16
<b>export</b> 13:5 23:19	28:12	<b>go</b> 3:9,16,18,19	<b>hereto</b> 31:15
25:19	<b>follows</b> 14:15 15:6	4:3 10:7 11:1	32:11
<b>exporter</b> 26:3	<b>food</b> 1:6 24:14	<b>goal</b> 7:3 21:10	<b>hicks</b> 2:3 16:6,11
<b>exporting</b> 23:17	<b>foods</b> 4:17	<b>goals</b> 4:19 5:18	30:15
<b>express</b> 17:20	<b>foregoing</b> 31:3,4	<b>going</b> 3:21 7:1	<b>high</b> 19:4 24:8,8
20:18 22:15	32:4	12:5 16:15	25:1
<b>extent</b> 5:2	<b>foreign</b> 5:1	<b>good</b> 3:2 17:11	<b>highest</b> 7:6 19:18
<b>f</b>	<b>form</b> 6:3,10 8:4	27:1	22:6
<b>facilitate</b> 4:20,21	9:11 10:18	<b>government</b> 5:1	<b>highlight</b> 9:16
13:11	<b>formal</b> 16:8	<b>greater</b> 28:8	<b>highlights</b> 22:22
<b>facilities</b> 3:15	<b>formed</b> 6:16	<b>group</b> 6:2 10:17	<b>hilley</b> 2:16 26:22
<b>facing</b> 23:16	<b>formulate</b> 11:2	11:13,17 12:2,9	27:1,2
<b>factors</b> 24:1	<b>forum</b> 18:3 20:1	12:17 28:10,20	<b>hold</b> 7:19 8:4
<b>fair</b> 24:15	<b>forward</b> 20:6	<b>groups</b> 6:20 8:3	<b>holding</b> 17:14
<b>family</b> 30:8	21:12	15:3	22:11
<b>fda</b> 2:2,4,12 3:4	<b>founded</b> 18:9 22:1	<b>group's</b> 12:3	<b>honest</b> 18:15
4:14 5:17 16:1	<b>four</b> 6:13	<b>growth</b> 13:4 24:1	<b>hopefully</b> 3:5
17:14,20 19:20			

<b>hoping</b> 29:22 <b>host</b> 14:15 <b>hosted</b> 9:17 <b>hosting</b> 7:21 9:17 14:22 <b>housekeeping</b> 3:10 <b>hslf</b> 27:22 <b>hsus</b> 27:22 <b>human</b> 29:6 <b>humane</b> 2:16,17 27:3,4 29:7,8 30:8 <b>hurdles</b> 25:20	20:14,15 24:1 <b>importantly</b> 20:2 <b>include</b> 4:20 12:10 <b>included</b> 6:13,20 <b>includes</b> 9:20 25:9 <b>including</b> 27:6 29:11 <b>increase</b> 13:11 <b>india</b> 27:7 <b>individuals</b> 8:21 9:19 <b>industries</b> 22:12 <b>industry</b> 7:2,2 8:12 9:21 10:5 13:10 14:18 17:17 18:9,18,20,20 19:7 20:2,17 21:2 22:17 24:2 26:17 28:10,16 29:11 <b>industry's</b> 17:19 <b>inform</b> 6:6 <b>information</b> 8:7 8:16 9:4,6,10 11:1 11:20 14:5 15:4 16:13,18 18:3,16 29:16 30:1 <b>ingredients</b> 10:2 10:10,12 15:8 20:15 23:6 24:17 25:7,9,13 28:12 28:22 29:4 <b>innovation</b> 19:8 <b>innovative</b> 19:4 <b>input</b> 7:2 16:1 <b>instructions</b> 4:8 15:15,18 <b>instructive</b> 28:15 <b>integral</b> 7:1 <b>integrated</b> 10:1,9 10:11 15:7 20:14 23:4 28:11 <b>intended</b> 13:13 <b>interest</b> 17:15 20:19 22:22	<b>interested</b> 21:4 22:12 31:15 32:12 <b>interests</b> 23:10 <b>interim</b> 7:19 15:2 <b>international</b> 1:2 3:6,22 4:12,15,20 5:10,12,19 6:19 7:5 11:6 14:14 15:10 19:6,11,19 21:6,8 22:17 24:22 26:17,19 29:6 <b>internationally</b> 25:3 28:5 <b>introduce</b> 5:18 <b>introduction</b> 18:6 <b>invest</b> 29:18 <b>invite</b> 16:1 <b>iso</b> 11:7,9,13 21:7 <b>israel</b> 12:21,22 20:22 22:20 27:7 <b>issue</b> 26:7 <b>issues</b> 4:5 7:10 13:8 23:13,16 <b>item</b> 15:18,19 16:4 16:8 20:12 <b>items</b> 3:10 4:9 6:7 6:8 10:1,21 15:11 15:15 16:2,3 <b>it's</b> 8:11 14:2 17:3 <b>i'd</b> 3:19 15:13 17:14 30:12,14 <b>i'll</b> 4:2,3 7:18 10:7 <b>i'm</b> 3:2,3,21 17:12 21:17 <b>i've</b> 9:3	<b>job</b> 1:13 <b>johnathan</b> 2:3 <b>joint</b> 10:17 11:12 11:17 12:3,9,17 28:10 <b>jon</b> 30:15 <b>jonathan</b> 16:6,11 30:14 <b>jonathan.hicks</b> 2:7 <b>juanita</b> 30:16 <b>july</b> 3:8 12:19 15:1 <b>june</b> 1:4 <b>jurisdiction</b> 13:15 <b>jurisdictions</b> 14:17
<b>i</b>			<b>k</b>
<b>iccr</b> 1:3 3:7,22 4:3 4:4,6,9,11 6:9,10 6:11 7:16,22 8:2,4 8:5,8 9:2,9,13,17 9:17,19,22 10:15 10:16,19 11:12 12:8 14:2,15,16 14:21 15:15,21 16:2,9,9,10,12,17 16:19 17:2,5,16 17:19 18:1,2,19 19:17,22 20:7,13 20:16,19,21 21:3 21:5,6,13 22:14 22:16,21,22 23:3 23:8 26:9,13,16 26:18 28:6 <b>iccr's</b> 9:3 10:10 <b>ich</b> 6:20 <b>identifying</b> 20:10 30:1 <b>ii</b> 10:12 28:12 <b>iii</b> 10:20,22 <b>imagine</b> 26:2 <b>implementation</b> 30:4 <b>import</b> 27:10 <b>importance</b> 14:3 <b>important</b> 14:2 18:4 19:20 20:1			<b>katz</b> 2:11 3:2,2 21:15 26:21 30:10 <b>key</b> 5:7 <b>know</b> 6:3 16:5,16 <b>knowledge</b> 4:22 31:10 32:6 <b>known</b> 5:13 13:9 <b>korea</b> 12:21 13:4 20:22 22:20 27:16
			<b>l</b>
			<b>labeling</b> 22:4 23:18 24:15 26:11 <b>latest</b> 22:3 <b>lauder</b> 29:12 <b>law</b> 5:2,8 <b>laws</b> 17:1 27:9,17 27:21 <b>leading</b> 18:7 29:6 29:10 <b>leave</b> 3:14,15 <b>led</b> 17:5 <b>left</b> 9:3 <b>legislative</b> 2:17 27:4 29:8,15
		<b>j</b>	
		<b>japan</b> 5:16 6:14 14:15 17:21 <b>japanese</b> 14:18 28:1 <b>jay</b> 2:13 17:9,12 21:15	

<b>level</b> 5:5 7:6 19:13 19:18 <b>license</b> 12:22 <b>light</b> 23:15 <b>limitations</b> 10:14 <b>limiting</b> 27:17 <b>linda</b> 2:11 3:2 17:11 20:7 <b>line</b> 16:1 26:19 <b>lip</b> 26:8 <b>list</b> 25:7,8 <b>listed</b> 25:12 <b>listening</b> 26:20 <b>lists</b> 25:11 <b>little</b> 4:5 10:7 <b>located</b> 21:19 <b>location</b> 1:6 <b>locations</b> 9:12 <b>look</b> 21:12 <b>looked</b> 14:9 <b>looking</b> 20:3,6 <b>loss</b> 29:12 <b>lowering</b> 5:7 <b>lush</b> 29:13	<b>markets</b> 18:4,21 24:9 <b>mary</b> 2:16 26:22 27:1 <b>maryland</b> 31:20 <b>materials</b> 25:10 30:2 <b>md</b> 1:11 2:6 <b>means</b> 12:11 <b>measures</b> 29:15 <b>medicinal</b> 26:1 <b>meet</b> 15:3 <b>meeting</b> 3:5,7 4:6 5:14 6:12 7:19,22 8:4,5,9,10,11,13 8:14 9:2 10:19,22 12:19 14:15,16 15:5,12 16:7,9,12 17:5,15 20:7 21:1 22:9 23:8,11,17 30:11,20 <b>meetings</b> 7:16 20:19 22:11 <b>member</b> 17:1 18:10 19:1,14 27:6 <b>members</b> 6:12,13 8:8 22:1,7,16 23:9 23:12,16,16 25:18 26:16 27:5 28:8 <b>memorandum</b> 5:21 <b>mentioned</b> 14:22 20:7,8 <b>message</b> 12:14 <b>messaging</b> 12:13 <b>met</b> 5:5,22 6:1 14:11 30:16 <b>methodologies</b> 10:15 28:15 <b>methods</b> 10:3 11:4 11:6 12:4 23:6 <b>microbiome</b> 10:4 12:17 15:11 20:12	<b>migrated</b> 15:22 <b>minimize</b> 7:4 19:17 <b>minimizing</b> 13:22 19:19 <b>minutes</b> 3:21 <b>model</b> 6:18,19 <b>monoxide</b> 25:15 <b>month</b> 4:7 <b>months</b> 21:14 <b>montreal</b> 3:8 4:8 9:15 14:22 <b>mutual</b> 4:21	<b>number</b> 25:12 <b>numerous</b> 28:14
<p style="text-align: center;"><b>m</b></p>		<p style="text-align: center;"><b>n</b></p>	<p style="text-align: center;"><b>o</b></p>
<b>maintain</b> 19:18 <b>majority</b> 18:11 23:16 <b>making</b> 29:17 <b>manufacture</b> 18:10 22:4 24:6 25:8 <b>manufacturers</b> 2:15 21:19,21 24:12,21 <b>manufacturer's</b> 24:19 <b>manufacturing</b> 25:6,14 26:11 <b>market</b> 13:5 21:22 24:18 25:2 26:3,5 <b>marketed</b> 18:12 <b>marketing</b> 23:13 25:21		<b>n</b> 2:1 3:1 <b>name</b> 17:12 27:1 <b>nams</b> 29:3 30:4 <b>natalia</b> 1:12 31:2 31:18 <b>national</b> 18:7 <b>nations</b> 13:9 <b>necessary</b> 28:4 <b>need</b> 3:14,18 29:1 30:7 <b>needed</b> 26:3 <b>needs</b> 16:15,19 30:1 <b>neither</b> 31:11 32:7 <b>never</b> 6:4 25:13 <b>new</b> 10:14 12:9,17 13:5 15:11 20:12 22:19 24:12 27:12 28:14 29:1,5,17 29:20 30:7 <b>nice</b> 6:2 <b>non</b> 12:4 21:20 28:16 29:9 <b>norway</b> 27:7 <b>notable</b> 13:4 <b>notary</b> 1:12 31:1 31:19 <b>note</b> 14:2 <b>notification</b> 13:6	<b>o</b> 3:1 <b>observed</b> 22:21 <b>observers</b> 21:1 28:7 <b>observing</b> 10:4 12:20 <b>obstacles</b> 7:4,5 <b>occasionally</b> 8:22 <b>occurred</b> 10:8 <b>october</b> 4:13 <b>office</b> 2:11 3:3 22:8 26:15 <b>officer</b> 31:2 <b>officials</b> 5:1 <b>oh</b> 3:21 <b>okay</b> 3:20 4:11 5:15 <b>once</b> 17:18 <b>open</b> 8:18 11:12 14:17 18:21 <b>opportunities</b> 30:3 <b>opportunity</b> 17:18 27:2 30:13 <b>opposed</b> 14:10 <b>oral</b> 16:4 <b>organization</b> 18:14 21:20 22:2 <b>organizations</b> 5:11 21:6 30:9 <b>organized</b> 17:3 <b>outcome</b> 31:16 32:12 <b>outcomes</b> 4:4 8:14 9:2 12:19 23:3 <b>overarching</b> 4:19
		<p style="text-align: center;"><b>p</b></p>	<p style="text-align: center;"><b>p</b></p>
			<b>p</b> 2:1,1 3:1 <b>p.m.</b> 1:5

<p><b>packaging</b> 24:15  <b>page</b> 2:10  <b>pain</b> 1:8  <b>pallet</b> 11:19  <b>paper</b> 10:13 11:3 11:18  <b>paperwork</b> 26:2  <b>park</b> 1:11 2:6  <b>parkway</b> 1:8  <b>part</b> 7:8 10:12,20 10:21,22 11:1 16:3 28:12,13 29:22  <b>participants</b> 5:15 5:15  <b>participate</b> 8:6,22 23:7  <b>participated</b> 9:19 14:17  <b>participating</b> 17:21 20:19  <b>participation</b> 8:20 8:21 17:22 21:2 22:19 28:6  <b>particular</b> 8:22  <b>particularly</b> 20:20  <b>parties</b> 22:12 31:12,14 32:8,11  <b>partners</b> 5:19 7:2 9:21  <b>passed</b> 27:9,16  <b>pcpc</b> 19:10  <b>people</b> 3:12 15:16 30:13  <b>permissible</b> 5:2  <b>personal</b> 2:13 3:11 17:10,13 18:5,6,9 18:11,16,19 19:5 21:9  <b>pertinent</b> 9:10  <b>petroleum</b> 25:15  <b>phones</b> 3:11  <b>planned</b> 28:20</p>	<p><b>planning</b> 22:9  <b>plans</b> 26:18  <b>playing</b> 19:14  <b>please</b> 3:16 16:5 16:10  <b>pleased</b> 17:17 18:18 20:20 23:7  <b>plus</b> 8:12  <b>point</b> 13:17  <b>policies</b> 20:1  <b>policy</b> 4:12  <b>policymakers</b> 18:14  <b>post</b> 14:5  <b>posted</b> 8:16 9:3 10:15 11:10 12:7 17:7  <b>potential</b> 12:5 20:11  <b>preparation</b> 1:1 3:6 10:21 23:8,11  <b>prepare</b> 8:15  <b>prepared</b> 32:3  <b>presentation</b> 16:4  <b>presentations</b> 10:6 13:12,19,20  <b>presented</b> 13:10 15:5  <b>presenting</b> 12:19  <b>preservation</b> 10:3 11:16,19,21 15:9 20:9  <b>preservative</b> 11:19  <b>preservatives</b> 11:22  <b>president</b> 2:14 17:13 21:18  <b>press</b> 8:15 9:11  <b>previous</b> 9:8 15:17  <b>previously</b> 14:11 30:12  <b>principles</b> 28:13</p>	<p><b>prior</b> 8:5 9:8 31:5  <b>private</b> 22:12  <b>probably</b> 3:21  <b>proceeding</b> 32:4  <b>proceedings</b> 31:3 31:5,6,9 32:6  <b>process</b> 4:3 6:6 7:16 17:19 18:1 18:19 21:3,13  <b>processes</b> 17:16  <b>proctor</b> 29:13  <b>producing</b> 22:6  <b>product</b> 10:3 11:15 15:9 19:15 26:4,6  <b>products</b> 2:13 4:16 17:10,14 18:5,7,9,12,17 19:5 21:9 22:4,6 23:14,22 24:2,7,8 24:17,20 25:1,2 25:19,22 26:8 29:12  <b>profit</b> 21:20  <b>program</b> 13:1  <b>programs</b> 5:4,5 17:13 29:19  <b>prohibit</b> 27:15,19 27:21  <b>prohibited</b> 27:13  <b>project</b> 29:5,22  <b>promote</b> 4:21 5:1 21:4  <b>promotes</b> 19:7  <b>promotion</b> 26:17  <b>proposals</b> 4:9  <b>proposed</b> 15:11  <b>protection</b> 5:6,8 7:6 13:12 19:19 22:5  <b>provide</b> 7:22  <b>provides</b> 24:7  <b>providing</b> 19:3</p>	<p><b>public</b> 1:12 3:5 5:6,8 8:4 16:1 31:1,19  <b>publication</b> 28:13  <b>publicly</b> 8:17 9:10  <b>published</b> 8:9  <b>push</b> 27:20</p> <p style="text-align: center;"><b>q</b></p> <p><b>qualified</b> 31:7  <b>quality</b> 19:4 22:6 24:8 25:1  <b>quarterly</b> 7:21 15:2  <b>questions</b> 16:16</p> <p style="text-align: center;"><b>r</b></p> <p><b>r</b> 2:1 3:1  <b>reach</b> 22:22  <b>real</b> 29:18  <b>really</b> 4:12 6:4,6  <b>reason</b> 3:14 15:21 26:9  <b>reasons</b> 19:10  <b>recognized</b> 14:3 20:16  <b>recognizes</b> 26:14  <b>recommend</b> 17:1  <b>record</b> 31:9 32:5  <b>recorded</b> 31:6  <b>recording</b> 31:8 32:4  <b>reduced</b> 31:7  <b>reference</b> 6:17  <b>refinery</b> 25:15  <b>regard</b> 10:9 13:19 14:13  <b>regarding</b> 23:18  <b>region</b> 7:21 8:22  <b>regions</b> 7:4,17 23:1 25:17  <b>register</b> 8:10  <b>registration</b> 13:1 30:17</p>
---	--	--	--

<p><b>regulate</b> 24:6  <b>regulated</b> 4:16  24:3 30:5  <b>regulates</b> 24:13  <b>regulation</b> 1:3 3:7  7:15 14:14 25:5  26:10,19  <b>regulations</b> 4:1  13:3 17:2 20:1  22:3 23:2 24:4,11  28:3  <b>regulators</b> 8:11,12  9:20 10:5 12:20  14:20 17:21 18:13  19:21 20:17 21:13  28:2 30:5  <b>regulators'</b> 8:13  <b>regulatory</b> 4:22  5:19,20 6:4 7:4,10  18:4,22 19:2,12  20:4 21:10 23:21  24:3,21,22 25:20  28:4 29:3  <b>regulator's</b> 28:10  <b>reinforcing</b> 19:15  <b>related</b> 12:10  22:13 31:11 32:7  <b>relationships</b> 6:3  6:4  <b>relative</b> 11:19  31:13 32:10  <b>release</b> 9:11  <b>released</b> 28:9  <b>releases</b> 8:15  <b>relevant</b> 11:13  <b>relied</b> 18:14 22:2  <b>remember</b> 15:17  16:22  <b>remove</b> 7:3  <b>report</b> 10:13 11:8  12:5 20:8 28:9  <b>reported</b> 1:12  23:17</p>	<p><b>represent</b> 18:18  <b>representatives</b>  14:16 20:21 22:19  <b>representing</b> 18:8  <b>request</b> 16:15,15  <b>requested</b> 30:11  <b>requests</b> 16:10  26:12  <b>required</b> 7:10  24:16  <b>requirements</b> 13:7  23:19  <b>residents</b> 27:8  <b>resource</b> 20:3  <b>respectfully</b> 26:12  <b>responsibility</b>  18:17 24:19  <b>rest</b> 8:8  <b>result</b> 16:4  <b>results</b> 20:6 23:15  <b>retaining</b> 7:5  <b>reveals</b> 25:7  <b>review</b> 11:5 16:19  28:14  <b>reviewed</b> 20:18  <b>right</b> 13:17  <b>rio</b> 27:14  <b>risk</b> 30:6  <b>river</b> 2:5  <b>road</b> 2:5  <b>role</b> 19:20  <b>room</b> 3:15,16  30:14  <b>rotate</b> 7:17  <b>rules</b> 24:4</p> <hr/> <p style="text-align: center;"><b>s</b></p> <hr/> <p><b>s</b> 2:1 3:1  <b>safe</b> 12:1 19:4  <b>safety</b> 10:1,9,11  15:8 19:12,16  20:10,14 22:18  23:5,22 24:2,8,20  25:2 28:11,17,22  29:9,20 30:1,6</p>	<p><b>sale</b> 27:10,15,19  <b>saw</b> 8:9  <b>schemes</b> 5:19 7:11  <b>scientific</b> 4:22  18:15  <b>second</b> 8:12  <b>secretariat</b> 8:1  <b>secretary</b> 16:12  <b>see</b> 9:13 12:15  28:9,19 30:14  <b>seek</b> 5:19  <b>selling</b> 28:5  <b>sensitization</b> 12:5  <b>seriously</b> 18:17  <b>served</b> 19:22  <b>session</b> 8:19  <b>set</b> 6:17 22:3  24:22  <b>share</b> 8:7 29:16  <b>shed</b> 23:15  <b>show</b> 7:18 15:14  <b>shown</b> 22:11  <b>shows</b> 9:4 17:2  <b>signature</b> 31:17  32:14  <b>simplify</b> 28:4  <b>skills</b> 31:10 32:6  <b>skin</b> 12:5  <b>slide</b> 7:17 15:14  17:2  <b>slight</b> 24:9  <b>small</b> 24:11  <b>society</b> 2:16,17  27:3,4 29:6,7,8  30:8  <b>solicit</b> 28:6  <b>soliciting</b> 17:15  <b>solved</b> 6:5  <b>someone's</b> 7:14  <b>south</b> 12:21,21  13:1,4 20:22,22  22:20,20 27:16  <b>southeast</b> 13:9</p>	<p><b>speak</b> 23:8 26:12  30:12  <b>speaker</b> 17:9  26:22  <b>speaking</b> 3:13  <b>specific</b> 6:8 14:8  14:11 16:2,16  <b>specifically</b> 5:17  <b>staff</b> 26:16 30:16  <b>stakeholder</b> 8:18  8:19 10:6 13:19  <b>stakeholders</b> 8:6  13:20 17:16 29:11  <b>stakeholder's</b>  8:20  <b>standards</b> 5:3  6:18 11:6,9,13  15:10 19:3,12  22:3  <b>started</b> 3:9,20  4:12 9:13  <b>state</b> 19:17 27:14  27:18 31:20  <b>states</b> 1:6 5:17  6:14 24:5 25:16  26:4 27:4,7,13  29:7  <b>steering</b> 6:16  10:10,16 11:5,16  12:2 28:7  <b>stimulate</b> 13:13  <b>strategies</b> 10:1,9  10:11 15:7 20:14  23:5 28:11,17  <b>strengths</b> 10:14  <b>stricter</b> 25:5  <b>stringent</b> 19:2  <b>strive</b> 19:1  <b>strong</b> 17:19  <b>strongly</b> 23:3  <b>structure</b> 8:10  <b>studies</b> 11:2 28:21  29:18</p>
---	---	--	--



<b>study</b> 10:18 <b>subgroup</b> 14:11 <b>subgroups</b> 14:10 <b>submit</b> 15:18 16:20 27:2 <b>submitting</b> 4:9 15:15 <b>subsidiary</b> 8:2 <b>success</b> 19:7 <b>suggest</b> 16:14 <b>suggestion</b> 13:16 <b>summarize</b> 10:8 <b>summary</b> 4:4 26:14 <b>sunscreen</b> 25:19 <b>sunscreens</b> 25:21 <b>supply</b> 18:11 <b>support</b> 17:19,22 29:6,19 <b>supporters</b> 27:5 <b>supporting</b> 16:18 22:16 <b>supports</b> 21:2,20 23:3 26:9 <b>sure</b> 8:16 16:11 <b>surpass</b> 19:2 <b>survey</b> 23:12,15 <b>switzerland</b> 27:8 <b>sworn</b> 31:5 <b>symposium</b> 14:14 <b>synergies</b> 21:5	<b>technologic</b> 19:8 <b>teleconferences</b> 15:2 <b>telephone</b> 7:20 <b>term</b> 6:17 <b>test</b> 10:2 11:4 23:6 29:1 <b>tested</b> 27:11,15,19 <b>testifying</b> 31:5 <b>testing</b> 13:6,21,22 14:1,4 23:18 27:9 27:14,17,21 28:17 29:16,18,21 <b>tests</b> 14:6,8 30:7 <b>th</b> 15:1,1 <b>thailand</b> 12:22 13:7 21:1 22:20 <b>thank</b> 17:8,11,14 21:14,15 22:8 26:19,21 27:2 30:9,10,13,14,18 30:18 <b>there's</b> 16:18 <b>they've</b> 19:5 <b>thing</b> 12:15 16:14 16:22 <b>think</b> 12:12 16:7 <b>third</b> 8:12 <b>thomas</b> 1:12 31:2 31:18 <b>thorough</b> 28:14 <b>three</b> 5:22 11:9 <b>time</b> 1:5 4:2,14,20 5:15,16 6:1,12,20 8:13 9:8 13:17 15:12,14 19:15 24:10 30:9 <b>times</b> 5:22 <b>tokyo</b> 9:14,19 23:4 <b>tools</b> 20:10 <b>toothpaste</b> 26:8 <b>topic</b> 14:4 16:20 <b>topics</b> 12:10 17:6	<b>trade</b> 4:20 7:2,3,5 13:8 18:7 19:13 19:20 21:8 26:19 29:16 <b>training</b> 29:19 30:2 <b>transcriber</b> 32:1 <b>transcript</b> 32:3,5 <b>transcriptionist</b> 31:8 <b>transparency</b> 5:2 <b>transparent</b> 18:21 <b>travel</b> 9:1 <b>true</b> 31:9 32:5 <b>truly</b> 18:20 <b>try</b> 11:21 <b>trying</b> 12:12 <b>turkey</b> 27:16 <b>turn</b> 3:11 17:8 <b>two</b> 8:19 <b>typewriting</b> 31:7	<b>updates</b> 10:4 <b>uphold</b> 19:2 22:5 <b>urge</b> 27:20 <b>use</b> 3:15 27:9 <b>useful</b> 9:6 <b>usually</b> 7:20 8:20
			<b>v</b>
			<b>validated</b> 14:7 <b>validation</b> 11:11 <b>variations</b> 24:9 <b>variety</b> 14:10 <b>various</b> 25:14,20 <b>varying</b> 4:16 <b>vast</b> 18:11 25:12 <b>venturini</b> 32:2,15 <b>venue</b> 22:13 <b>vice</b> 17:12 <b>vich</b> 6:21 <b>viewpoint</b> 17:16 <b>voice</b> 22:13 23:9 <b>voluntary</b> 6:18 7:9
		<b>u</b>	<b>w</b>
<b>t</b>		<b>u.s.</b> 2:16 5:8 8:3 9:16 18:12 21:20 24:10 25:9 26:3 28:1 <b>underscores</b> 19:20 <b>understanding</b> 4:21 <b>undertaken</b> 20:16 <b>uniformity</b> 28:4 <b>unilever</b> 29:13 <b>union</b> 5:16 6:14 24:5 25:5,12,17 26:5 27:7 <b>united</b> 1:6 5:17 6:14 24:5 25:16 26:4 27:3 29:7 <b>unlimited</b> 29:13 <b>upcoming</b> 4:5 13:6 15:5 <b>update</b> 10:5 11:13 13:10	<b>want</b> 12:15 <b>wanted</b> 3:9 <b>washington</b> 21:19 <b>way</b> 6:7 12:12 13:11 24:7 <b>website</b> 9:3,4,9 10:15 11:10 12:7 15:14,17,21 17:2 17:7 <b>wednesday</b> 1:4 <b>week</b> 4:7,7 <b>welcome</b> 20:20 30:3 <b>went</b> 13:15 <b>weren't</b> 6:6 <b>we'll</b> 26:21 <b>we're</b> 3:5 12:11 20:20 <b>we've</b> 7:18 9:6,12 14:5 15:2 17:7
<b>table</b> 11:13 13:16 13:16 <b>taiwan</b> 12:22 13:5 20:22 22:20 27:16 <b>take</b> 17:18 18:17 30:12 <b>taken</b> 31:3,12 32:9 <b>talk</b> 3:22 4:3,14 15:7,9 16:19 <b>talked</b> 13:4,7 <b>talks</b> 17:4			

<p><b>white</b> 10:13 11:3 11:18</p> <p><b>who's</b> 3:4 17:5</p> <p><b>wiley</b> 1:9</p> <p><b>wish</b> 16:3</p> <p><b>witness</b> 31:4</p> <p><b>work</b> 6:8 7:12,16 10:17 11:2,17 12:2,17 14:4 15:3 20:12,16 21:5 28:2,19 30:1,3,15</p> <p><b>worked</b> 10:19 12:6</p> <p><b>working</b> 8:2 10:17 11:12,17 12:3,9 21:12 28:10,20</p> <p><b>workshop</b> 20:14</p> <p><b>world</b> 18:22 19:9 29:18</p> <p><b>worldwide</b> 12:16 19:3</p> <p><b>writing</b> 16:5</p> <p><b>written</b> 16:10</p>
<b>y</b>
<p><b>yates</b> 30:16</p> <p><b>year</b> 8:1 9:7,14,14 14:13,22</p> <p><b>years</b> 7:18 15:16 18:13 21:14</p> <p><b>you'll</b> 25:11</p> <p><b>you're</b> 16:15</p>
<b>z</b>
<p><b>zealand</b> 27:12</p>